TABLE 1.
Bacterial strains and plasmids | Relevant featuresa | Source or reference |
---|---|---|
Strains | ||
S. clavuligerus | ||
NRRL 3585 | Wild type; cephamycin and clavulanic acid producer | NRRL |
E. coli | ||
XLI-blue | General cloning host | Stratagene |
ET12567(pUZ8002) | Methylation deficient; transfer functions from pUZ8002 | 15 |
Plasmids | ||
Cloning vectors | ||
pBluescript II KS(+) | E. coli general cloning vector, Ampr | Stratagene |
pSL1180 | E. coli general cloning vector, Ampr | Pharmacia |
pTZ18R | E. coli general cloning vector, Ampr | US Biochemicals |
pUC119 | E. coli general cloning vector, Ampr | 32 |
pSET152 | E. coli replicon, Streptomyces φC31 attachment site, aptr | NRRL |
pCR 2.1-TOPO | E. coli vector for cloning PCR products, Ampr | Invitrogen |
pJV326 | par-defective, oriT-containing, Streptomyces-E. coli shuttle | 9 |
pIJ486 | Streptomyces pIJ101 replicon, Tsrr | 33 |
pMT3226 | pSET152 derivative, xylE controlled by gylP1P2 promoters | 10, 31 |
Antibiotic resistance cassettes | ||
pUC120apr | Aprr cassette in pUC120 | 23 |
pSKNeo | Neor cassette in pBluescript II KS(+) | 20 |
Intermediate constructs | ||
K6L2 | E. coli cosmid carrying S. clavuligerus genomic DNA | 2 |
p667-3PB | middle of orf18 to end of orf19 in pUC119 | This study |
pCEC001 | Start of orf10 to middle of orf18 in pTZ18R | This study |
pCEC004 | Middle of orf13 to middle of orf16 in pBluescript II SK(+) | This study |
pCEC028 | Middle of orf12 to end of orf15 in pBluescript II SK(+) | This study |
pCEC062 | End of orf17 to middle of orf18 in pBluescript II KS(+) | This study |
Gene disruption constructs | ||
pLOG221 | orf11::apr disruption construct | This study |
pLOG 240 | orf12::apr disruption construct | This study |
pCEC046 | orf14::apr disruption construct | This study |
pCEC047 | orf13::apr disruption construct | This study |
pCEC063 | orf15::apr disruption construct | This study |
pCEC068 | orf16::apr disruption construct | This study |
pCEC076 | orf17::apr disruption construct | This study |
pCEC085 | orf18::neo disruption construct | This study |
pCEC086 | orf15-Δfs replacement construct | This study |
pCEC089 | orf19::apr disruption construct | This study |
pCEC179 | Δorf16 replacement construct | This study |
Gene insertion construct | ||
pMT8.34 | pgyl::orf18 construct in pSET152 | This study |
Abbreviations: Amp, ampicillin; Apr, apramycin; Neo, neomycin; Tsr, thiostrepton.